A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT05620823 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

608

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa (HS)

Interventions

DRUG: Povorcitinib
DRUG: Placebo

Sponsor

Incyte Corporation